TOP 100 MEDICAL SITES
| |||
|
| |||
| |||
|
| |||
| U.S. Life Science Sector Set for Stable Growth, Led by Equipment Makers Research Recap submits: The life science sector’s outlook remains stable, though equipment makers are set to outperform contract research organizations (CROs) over the next 12-18 months, Moody’s says in a new Industry Outlook. Manufacturers are set to benefit from an economic recovery, with sales of capital equipment benefiting from renewed spending in industrial and applied markets.Equipment makers will also get a boost from purchases by academic customers, benefitting in 2010 and 2011 from U.S. government stimulus spending directed at funding research.Upcoming patent expirations in the pharmaceutical industry will translate to cost-containment measures, constraining CROs’ growth, which depend heavily on business from pharmaceutical companies. Ongoing strategies to increase the level of outsourcing favors CROs and helps offset this pressure, and should continue over the long term.Progress in the integration of the 2009 pharmaceutical mega-mergers should translate into fewer R&D project cancellations and delays, lending stability to the life science sector.We expect no meaningful effect on life science companies from healthcare reform through 2011. We are generally more favorable on the outlook for manufacturers in the sector than for contract research organizations, mainly because the CROs depend far more on the pharmaceutical industry for revenue and profit.Complete Story » seekingalpha.com |
Merck in Talks for China Partnership Merck is in talks with China's Sinopharm for a venture to market vaccines and, potentially, Merck drugs. online.wsj.com |
Dionex Corporation F4Q10 (Qtr End 6-30-10) Earnings Call Transcript Dionex Corporation (DNEX)F4Q10 (Qtr End 6/30/10) Earnings CallAugust 12, 2010 4:30 pm ETComplete Story » seekingalpha.com |
The Orthopaedic & Spine Institute. - Video Close-Up TV News recognizes the Orthopaedic & Spine Institute for its remarkable commitment to quality care, providing relief to thousands of patients. feedproxy.google.com |
Slim Hopes for Obesity Drugs to Gain Approval The Burrill Report submits: By Michael FitzhughThe U.S. Food and Drug Administration’s rejection of Arena’s (ARNA) experimental obesity drug lorcaserin now shifts public attention to two other contenders set to come before the agency for review. Investors looking to cash in on a largely untapped market opportunity are left with thinning expectations for success. Complete Story » seekingalpha.com |